Intensiveret behandling af type 2-diabetes mellitus: Er polyfarmaci nødvendig og berettiget?

Oluf Borbye Pedersen*, Peter Haulund Gœde

*Corresponding author for this work

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Newly published randomised controlled trials with pharmacological intervention against hyperglycaemia, hypertension and dyslipidaemia have challenged the traditional empiric treatment of type 2-diabetes. This review focuses on the results of these trials as well as randomised trials with pharmacological therapy of microalbuminuria, primary prevention with acetylsalicylic acid and angiotensin converting enzyme (ACE) inhibitors. The overall results from these trials are clinically relevant reductions in the risk of late diabetic complications. Taken together, the new clinical knowledge does not mean that all patients with type 2-diabetes besides relevant changes in lifestyle will benefit from a comprehensive polypharmacy. It means, however, that based upon the individual risk profile the medical professionals have to motivate the patient for an evidence based "therapeutic package" which is likely to improve the longterm outcome.

    Original languageDanish
    Pages (from-to)3582-3591
    Number of pages10
    JournalUgeskrift for laeger
    Volume162
    Issue number25
    Publication statusPublished - 19 Jun 2000

    Cite this